Biogen (NASDAQ:BIIB) Cut to "Equal Weight" at Wells Fargo & Company
Wells Fargo & Company cut shares of Biogen (NASDAQ:BIIB – Free Report) from an overweight rating to an equal weight rating in a report issued on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has $240.00 price objective on the biotechnology company’s stock, down from their previous price objective of $315.00. A number of other […]